Clinical Trial

MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.

Study acronym: MSC303
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated June 11, 2025 (before its estimated May 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the safety and efficacy of MSC303 in patients with Immune glomerular diseases.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-29.
Trial Details
NCT Number NCT07000292
Lead Sponsor Shanghai Changzheng Hospital
Conditions Lupus Nephritis (LN), ANCA-Associated Glomerulonephritis
Enrollment 12 participants
Start Date 2025-06-20
Primary Completion 2026-05-20 (estimated)
Study Completion 2027-02-20 (estimated)
Updated on ClinicalTrials.gov 2025-06-11